Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

BACKGROUND: Mutations in KIT are more frequent in specific melanoma subtypes, and response to KIT inhibition is likely to depend on the identified mutation. METHODS: A total of 32 patients with metastatic acral or mucosal melanoma were screened for mutations in KIT exons 11, 13 and 17. RESULTS: KIT...

Descripción completa

Detalles Bibliográficos
Autores principales: Handolias, D, Hamilton, A L, Salemi, R, Tan, A, Moodie, K, Kerr, L, Dobrovic, A, McArthur, G A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856012/
https://www.ncbi.nlm.nih.gov/pubmed/20372153
http://dx.doi.org/10.1038/sj.bjc.6605635
Descripción
Sumario:BACKGROUND: Mutations in KIT are more frequent in specific melanoma subtypes, and response to KIT inhibition is likely to depend on the identified mutation. METHODS: A total of 32 patients with metastatic acral or mucosal melanoma were screened for mutations in KIT exons 11, 13 and 17. RESULTS: KIT mutations were found in 38% of mucosal and in 6% of acral melanomas. Three patients were treated with imatinib and one with sorafenib. All four patients responded to treatment, but three have since progressed within the brain. CONCLUSION: The observed clinical responses support further investigation of KIT inhibitors in metastatic melanoma, selected according to KIT mutation status.

Ejemplares similares